Telix Pharmaceuticals (TLPPF) Total Current Liabilities (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Total Current Liabilities for 4 consecutive years, with $242.3 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Current Liabilities changed N/A year-over-year to $242.3 million in Q2 2026; TTM through Jun 2026 was $242.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $231.6 million, up 12.94% from the prior year.
• Total Current Liabilities was $242.3 million for Q2 2026 at Telix Pharmaceuticals, up from $231.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $242.3 million in Q2 2026 and troughed at $107.5 million in Q4 2023.
• A 4-year average of $199.5 million and a median of $224.0 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 101.39% in 2024 and advanced 7.03% in 2025, its largest moves.
• Over 4 years, Total Current Liabilities stood at $107.5 million in 2023, then soared by 101.39% to $216.4 million in 2024, then grew by 7.03% to $231.6 million in 2025, then increased by 4.63% to $242.3 million in 2026.
• The last three Total Current Liabilities figures came in at $242.3 million (Q2 2026), $231.6 million (Q4 2025), and $216.4 million (Q4 2024), per Business Quant data.